Massivemarkets

MBRX

Moleculin Biotech, Inc.

Nasdaq · usd

$7.84-0.22 (-2.73%)
As of 4:59:46 AM EST on Nov 13, 2026 · 15-minute delayed

Moleculin Biotech, Inc. (MBRX) trades at $7.84 (-2.73%) as of 4:59:46 AM EST on Nov 13, 2026, -1.95% over the past month. Market cap is $8.22M, with 1.0 days to cover in short interest.

Stock performance

How Moleculin Biotech, Inc. (MBRX) stock has performed from one day to one year, with its 52-week range.

-94.09%
-$128.29 over 1Y
$16.25$53.50$90.75$128.00Nov 25Feb 26May 26Aug 26Nov 26$8.06
1D
-0.49%
1W
-7.67%
1M
-1.95%
YTD
-87.82%
1Y
-96.28%
52-wk range
$3.23 – $229.40

Key statistics

Today's trading snapshot for MBRX: day range, open, previous close, volume and market cap.

Day range
—
Open
—
Prev close
$8.06
Volume
400
Market cap
$8.22M
Shares out
1.02M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Moleculin Biotech, Inc.: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
0.71
P/FCF
—
ROE
-280.7%
ROA
-154.2%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 11, 2026

8-K filings

Material corporate events Moleculin Biotech, Inc. has disclosed to the SEC on Form 8-K.

  • Patent milestoneNov 12, 2026

    On November 12, 2026, Moleculin Biotech, Inc. issued a press release which announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company's intellectual property protection for a key aspect of Annamycin's formulation technology. Australian Patent No. 2020303572 was granted to Moleculin and The Board of Regents of The University of Texas System.

  • Charter amendmentOct 20, 2026

    The stockholders of the Company approved an amendment to the Company's amended and restated certificate of incorporation... to effect the reverse stock split... The Amendment was filed with the Secretary of State of the State of Delaware.

  • Investor presentationOct 16, 2026

    On October 16, 2026, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.

  • Annual meeting resultsOct 9, 2026

    The authorization to allow for the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes ... was approved. The votes on the matter were: Votes For 6,116,006; Votes Against 1,979,187; Abstain 151,896.

  • Investor presentationOct 5, 2026

    On October 5, 2026, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.

Dividend history and stock splits

Moleculin Biotech, Inc.'s recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-20Oct 20, 2026
  • 1-for-25Dec 1, 2025
  • 1-for-15Mar 22, 2024

MBRX short interest

How heavily MBRX is shorted: shares short, days to cover and average daily volume.

Days to cover
1.0
Short interest
54.54K
Avg volume
67.65K

As of · reported to FINRA twice monthly.

MBRX news

The latest news and headlines about Moleculin Biotech, Inc. (MBRX).

Frequently asked questions

What is the Moleculin Biotech, Inc. (MBRX) stock price today?

Moleculin Biotech, Inc. (MBRX) is trading at $7.84 (-2.73% on the day) as of 4:59:46 AM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Moleculin Biotech, Inc.?

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical…

What is the short interest in MBRX?

As of Oct 30, 2026, MBRX has 54.54K shares short and 1.0 days to cover.

What exchange is MBRX listed on?

Moleculin Biotech, Inc. (MBRX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of MBRX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MBRX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.